Literature DB >> 25288184

Discovery of substituted 4-aminoquinazolines as selective Toll-like receptor 4 ligands.

Afshin Nour1, Tomoko Hayashi1, Michael Chan1, Shiyin Yao1, Rommel I Tawatao1, Brian Crain1, Igor F Tsigelny2, Valentina L Kouznetsova3, Alast Ahmadiiveli1, Karen Messer1, Minya Pu1, Maripat Corr4, Dennis A Carson1, Howard B Cottam1.   

Abstract

The Toll-like receptors (TLRs) are critical components of the innate immune system that regulate immune recognition in part through NF-κB activation. A human cell-based high throughput screen (HTS) revealed substituted 4-aminoquinazolines to be small molecular weight activators of NF-κB. The most potent hit compound predominantly stimulated through the human TLR4/MD2 complex, and had less activity with the mouse TLR4/MD2. There was no activity with other TLRs and the TLR4 activation was MD-2 dependent and CD14 independent. Synthetic modifications of the quinazoline scaffold at the 2 and 4 positions revealed trends in structure-activity relationships with respect to TLR dependent production of the NF-κB associated cytokine IL-8 in human peripheral blood mononuclear cells, as well as IL-6 in mouse antigen presenting cells. Furthermore, the hit compound in this series also activated the interferon signaling pathway resulting in type I interferon production. Substitution at the O-phenyl moiety with groups such as bromine, chlorine and methyl resulted in enhanced immunological activity. Computational studies indicated that the 4-aminoquinazoline compounds bind primarily to human MD-2 in the TLR4/MD-2 complex. These small molecules, which preferentially stimulate human rather than mouse innate immune cells, may be useful as adjuvants or immunotherapeutic agents.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  4-Aminoquinazolines; Innate immune response; MD-2; NF-κB activation; Toll-like receptor 4

Mesh:

Substances:

Year:  2014        PMID: 25288184      PMCID: PMC4250372          DOI: 10.1016/j.bmcl.2014.09.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  18 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex.

Authors:  Beom Seok Park; Dong Hyun Song; Ho Min Kim; Byong-Seok Choi; Hayyoung Lee; Jie-Oh Lee
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

3.  Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response.

Authors:  Hongliang Fang; Yanfeng Wu; Xiaohui Huang; Wenying Wang; Bing Ang; Xuetao Cao; Tao Wan
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

4.  MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex.

Authors:  Stephen R Coats; Thu-Thao T Pham; Brian W Bainbridge; Robert A Reife; Richard P Darveau
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

Review 5.  NF-κB and innate immunity.

Authors:  Anurupa Dev; Shankar Iyer; Bahram Razani; Genhong Cheng
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

6.  HexServer: an FFT-based protein docking server powered by graphics processors.

Authors:  Gary Macindoe; Lazaros Mavridis; Vishwesh Venkatraman; Marie-Dominique Devignes; David W Ritchie
Journal:  Nucleic Acids Res       Date:  2010-05-05       Impact factor: 16.971

Review 7.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

8.  Euodenine A: a small-molecule agonist of human TLR4.

Authors:  Juliette E Neve; Hasanthi P Wijesekera; Sandra Duffy; Ian D Jenkins; Justin A Ripper; Simon J Teague; Marc Campitelli; Agatha Garavelas; George Nikolakopoulos; Phuc V Le; Priscila de A Leone; Ngoc B Pham; Philip Shelton; Neil Fraser; Anthony R Carroll; Vicky M Avery; Christopher McCrae; Nicola Williams; Ronald J Quinn
Journal:  J Med Chem       Date:  2014-02-07       Impact factor: 7.446

9.  Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands.

Authors:  Michael Chan; Tomoko Hayashi; Richard D Mathewson; Afshin Nour; Yuki Hayashi; Shiyin Yao; Rommel I Tawatao; Brian Crain; Igor F Tsigelny; Valentina L Kouznetsova; Karen Messer; Minya Pu; Maripat Corr; Dennis A Carson; Howard B Cottam
Journal:  J Med Chem       Date:  2013-05-24       Impact factor: 7.446

10.  Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica.

Authors:  Adeline M Hajjar; Robert K Ernst; Edgardo S Fortuno; Alicia S Brasfield; Cathy S Yam; Lindsay A Newlon; Tobias R Kollmann; Samuel I Miller; Christopher B Wilson
Journal:  PLoS Pathog       Date:  2012-10-11       Impact factor: 6.823

View more
  7 in total

Review 1.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

2.  Structure-Activity Relationship Studies of Pyrimido[5,4-b]indoles as Selective Toll-Like Receptor 4 Ligands.

Authors:  Michael Chan; Yuhei Kakitsubata; Tomoko Hayashi; Alast Ahmadi; Shiyin Yao; Nikunj M Shukla; Shin-Ya Oyama; Akihito Baba; Brandon Nguyen; Maripat Corr; Yasuo Suda; Dennis A Carson; Howard B Cottam; Masahiro Wakao
Journal:  J Med Chem       Date:  2017-11-03       Impact factor: 7.446

3.  Identification of Biologically Active Pyrimido[5,4-b]indoles That Prolong NF-κB Activation without Intrinsic Activity.

Authors:  Michael Chan; Alast Ahmadi; Shiyin Yao; Fumi Sato-Kaneko; Karen Messer; Minya Pu; Brandon Nguyen; Tomoko Hayashi; Maripat Corr; Dennis A Carson; Howard B Cottam; Nikunj M Shukla
Journal:  ACS Comb Sci       Date:  2017-07-13       Impact factor: 3.784

4.  A Light-Controlled TLR4 Agonist and Selectable Activation of Cell Subpopulations.

Authors:  Lalisa Stutts; Aaron P Esser-Kahn
Journal:  Chembiochem       Date:  2015-06-26       Impact factor: 3.164

5.  Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.

Authors:  Alex C D Salyer; Giuseppe Caruso; Karishma K Khetani; Lauren M Fox; Subbalakshmi S Malladi; Sunil A David
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

6.  A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation.

Authors:  Jason D Marshall; Darren S Heeke; Eileen Rao; Sean K Maynard; David Hornigold; Christopher McCrae; Neil Fraser; Andrey Tovchigrechko; Li Yu; Nicola Williams; Sarah King; Martin E Cooper; Adeline M Hajjar; Jennifer C Woo
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

Review 7.  The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling.

Authors:  Florent Cochet; Francesco Peri
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.